OMER - Omeros: An IOMachine Review Of OMS721 In HSCT-TMA
Omeros Corporation (OMER) has been a real puzzle for years. Some years ago, when its drug Omidria's pass-through status was about to be rescinded, we wrote positively about the stock, saying, one, that they will get back pass-through status, and two, OMS721 is the key (read our previous coverage to know the story). They did get back pass-through status, and OMS721 has nicely progressed through trials and key regulatory processes.
On the other hand, a section of the investor/analyst community is very anti-OMER. We have seen this over the years. Each time they make a